Cases and Deals
Deal

Intellipharmaceutics International Inc. in a Public Offering

Blank Rome represented Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs in a $3.1 million public offering of units of common shares and warrants. The transaction closed in July 2013.